Genome Protection

About Genome Protection

Genome Protection Inc. (GPI) is a clinical-stage biotechnology company founded in 2018 as a joint venture between Cleveland BioLabs, Inc. and Everon Biosciences, Inc. The company's mission is to safeguard DNA to extend healthy lifespans by developing treatments for cancer and age-related diseases. GPI is headquartered in Buffalo, New York.

The company was co-founded by Andrei Gudkov Ph.D., Bertrand Alexandre, and Yakov Kogan Ph.D. The founders and scientific team have backgrounds in studying the genome's role in aging and cancer. GPI's core technology focuses on neutralizing endogenous retroelements, also referred to as the 'retrobiome', which are ancient viruses that can cause intrinsic DNA damage. By suppressing these retrotransposons, the company aims to prevent genomic instability, a key factor in aging and disease. Their research and development program creates small molecule drugs designed to inhibit these retroelements and stimulate innate immune functions that weaken with age.

Genome Protection operates in the drug discovery and biotechnology sectors, with a focus on longevity, oncology, and HealthTech. The business model involves developing these novel drugs and advancing them through clinical testing. The company collaborates with research institutions like Roswell Park Comprehensive Cancer Center and the Mayo Clinic to conduct clinical trials. Revenue and growth are supported by venture capital funding, grants, and strategic partnerships. GPI has received investments from entities including the United States Department of Defense, Cleveland Biolabs, Everon Biosciences, and Norma Investments Limited.